nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—BCHE—diaphragm—ovarian cancer	0.0527	0.194	CbGeAlD
Triamcinolone—SERPINA6—oviduct—ovarian cancer	0.0407	0.15	CbGeAlD
Triamcinolone—PTGS2—ovarian follicle—ovarian cancer	0.0351	0.129	CbGeAlD
Triamcinolone—CYP3A4—Topotecan—ovarian cancer	0.0114	0.354	CbGbCtD
Triamcinolone—CYP3A4—Vinorelbine—ovarian cancer	0.00806	0.25	CbGbCtD
Triamcinolone—SERPINA6—female reproductive system—ovarian cancer	0.00759	0.028	CbGeAlD
Triamcinolone—SERPINA6—bone marrow—ovarian cancer	0.00716	0.0264	CbGeAlD
Triamcinolone—BCHE—myometrium—ovarian cancer	0.0064	0.0236	CbGeAlD
Triamcinolone—NR3C1—myometrium—ovarian cancer	0.0057	0.021	CbGeAlD
Triamcinolone—CYP3A4—Paclitaxel—ovarian cancer	0.00567	0.175	CbGbCtD
Triamcinolone—NR3C1—embryo—ovarian cancer	0.00548	0.0202	CbGeAlD
Triamcinolone—BCHE—uterine cervix—ovarian cancer	0.00498	0.0184	CbGeAlD
Triamcinolone—PTGS2—myometrium—ovarian cancer	0.00493	0.0182	CbGeAlD
Triamcinolone—PTGS2—embryo—ovarian cancer	0.00474	0.0175	CbGeAlD
Triamcinolone—BCHE—endometrium—ovarian cancer	0.00451	0.0166	CbGeAlD
Triamcinolone—NR3C1—epithelium—ovarian cancer	0.00447	0.0165	CbGeAlD
Triamcinolone—NR3C1—uterine cervix—ovarian cancer	0.00443	0.0164	CbGeAlD
Triamcinolone—NR3C1—decidua—ovarian cancer	0.00423	0.0156	CbGeAlD
Triamcinolone—BCHE—uterus—ovarian cancer	0.00415	0.0153	CbGeAlD
Triamcinolone—CYP3A4—Docetaxel—ovarian cancer	0.0041	0.127	CbGbCtD
Triamcinolone—NR3C1—endometrium—ovarian cancer	0.00401	0.0148	CbGeAlD
Triamcinolone—PTGS2—epithelium—ovarian cancer	0.00387	0.0143	CbGeAlD
Triamcinolone—PTGS2—uterine cervix—ovarian cancer	0.00384	0.0142	CbGeAlD
Triamcinolone—BCHE—female reproductive system—ovarian cancer	0.00373	0.0138	CbGeAlD
Triamcinolone—NR3C1—gonad—ovarian cancer	0.00372	0.0137	CbGeAlD
Triamcinolone—NR3C1—uterus—ovarian cancer	0.0037	0.0136	CbGeAlD
Triamcinolone—BCHE—bone marrow—ovarian cancer	0.00352	0.013	CbGeAlD
Triamcinolone—PTGS2—endometrium—ovarian cancer	0.00347	0.0128	CbGeAlD
Triamcinolone—BCHE—vagina—ovarian cancer	0.00338	0.0125	CbGeAlD
Triamcinolone—NR3C1—female reproductive system—ovarian cancer	0.00332	0.0123	CbGeAlD
Triamcinolone—PTGS2—uterus—ovarian cancer	0.0032	0.0118	CbGeAlD
Triamcinolone—NR3C1—bone marrow—ovarian cancer	0.00314	0.0116	CbGeAlD
Triamcinolone—CYP3A4—Doxorubicin—ovarian cancer	0.00305	0.0945	CbGbCtD
Triamcinolone—NR3C1—female gonad—ovarian cancer	0.00302	0.0112	CbGeAlD
Triamcinolone—BCHE—testis—ovarian cancer	0.00301	0.0111	CbGeAlD
Triamcinolone—NR3C1—vagina—ovarian cancer	0.00301	0.0111	CbGeAlD
Triamcinolone—PTGS2—female reproductive system—ovarian cancer	0.00288	0.0106	CbGeAlD
Triamcinolone—PTGS2—bone marrow—ovarian cancer	0.00271	0.01	CbGeAlD
Triamcinolone—NR3C1—testis—ovarian cancer	0.00268	0.0099	CbGeAlD
Triamcinolone—PTGS2—female gonad—ovarian cancer	0.00262	0.00966	CbGeAlD
Triamcinolone—PTGS2—vagina—ovarian cancer	0.0026	0.0096	CbGeAlD
Triamcinolone—CYP3A4—female reproductive system—ovarian cancer	0.00251	0.00928	CbGeAlD
Triamcinolone—Fluticasone Propionate—PGR—ovarian cancer	0.00218	0.179	CrCbGaD
Triamcinolone—BCHE—lymph node—ovarian cancer	0.00218	0.00806	CbGeAlD
Triamcinolone—Betamethasone—PGR—ovarian cancer	0.002	0.164	CrCbGaD
Triamcinolone—NR3C1—lymph node—ovarian cancer	0.00194	0.00717	CbGeAlD
Triamcinolone—PTGS2—lymph node—ovarian cancer	0.00168	0.00621	CbGeAlD
Triamcinolone—Fluoxymesterone—ESR1—ovarian cancer	0.00162	0.133	CrCbGaD
Triamcinolone—Dexamethasone—PGR—ovarian cancer	0.00116	0.0952	CrCbGaD
Triamcinolone—Dexamethasone—CYP1B1—ovarian cancer	0.00109	0.089	CrCbGaD
Triamcinolone—Acute coronary syndrome—Docetaxel—ovarian cancer	0.00102	0.0016	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Docetaxel—ovarian cancer	0.00102	0.00159	CcSEcCtD
Triamcinolone—Myocardial infarction—Docetaxel—ovarian cancer	0.00102	0.00159	CcSEcCtD
Triamcinolone—Vascular purpura—Epirubicin—ovarian cancer	0.00101	0.00158	CcSEcCtD
Triamcinolone—Conjunctivitis—Docetaxel—ovarian cancer	0.00101	0.00157	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Epirubicin—ovarian cancer	0.001	0.00156	CcSEcCtD
Triamcinolone—Fatigue—Vinorelbine—ovarian cancer	0.001	0.00156	CcSEcCtD
Triamcinolone—Hypersensitivity—Topotecan—ovarian cancer	0.001	0.00156	CcSEcCtD
Triamcinolone—Pain—Vinorelbine—ovarian cancer	0.000992	0.00155	CcSEcCtD
Triamcinolone—Arrhythmia—Paclitaxel—ovarian cancer	0.000982	0.00153	CcSEcCtD
Triamcinolone—Hypersensitivity—Melphalan—ovarian cancer	0.000979	0.00153	CcSEcCtD
Triamcinolone—Epistaxis—Docetaxel—ovarian cancer	0.000978	0.00153	CcSEcCtD
Triamcinolone—Fluticasone furoate—ABCB1—ovarian cancer	0.000975	0.0798	CrCbGaD
Triamcinolone—Asthenia—Topotecan—ovarian cancer	0.000973	0.00152	CcSEcCtD
Triamcinolone—Thrombophlebitis—Doxorubicin—ovarian cancer	0.000971	0.00152	CcSEcCtD
Triamcinolone—Vomiting—Chlorambucil—ovarian cancer	0.000969	0.00151	CcSEcCtD
Triamcinolone—Increased appetite—Epirubicin—ovarian cancer	0.000966	0.00151	CcSEcCtD
Triamcinolone—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000966	0.00151	CcSEcCtD
Triamcinolone—Pruritus—Topotecan—ovarian cancer	0.00096	0.0015	CcSEcCtD
Triamcinolone—Erythema—Paclitaxel—ovarian cancer	0.000956	0.00149	CcSEcCtD
Triamcinolone—Feeling abnormal—Vinorelbine—ovarian cancer	0.000956	0.00149	CcSEcCtD
Triamcinolone—Asthenia—Melphalan—ovarian cancer	0.000953	0.00149	CcSEcCtD
Triamcinolone—Dermatitis bullous—Epirubicin—ovarian cancer	0.00095	0.00148	CcSEcCtD
Triamcinolone—Purpura—Epirubicin—ovarian cancer	0.000942	0.00147	CcSEcCtD
Triamcinolone—Pruritus—Melphalan—ovarian cancer	0.00094	0.00147	CcSEcCtD
Triamcinolone—Vascular purpura—Doxorubicin—ovarian cancer	0.000939	0.00147	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000938	0.00146	CcSEcCtD
Triamcinolone—Dysgeusia—Paclitaxel—ovarian cancer	0.000937	0.00146	CcSEcCtD
Triamcinolone—Haemoglobin—Docetaxel—ovarian cancer	0.000936	0.00146	CcSEcCtD
Triamcinolone—Rhinitis—Docetaxel—ovarian cancer	0.000934	0.00146	CcSEcCtD
Triamcinolone—Haemorrhage—Docetaxel—ovarian cancer	0.000931	0.00145	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000926	0.00145	CcSEcCtD
Triamcinolone—Back pain—Paclitaxel—ovarian cancer	0.000925	0.00144	CcSEcCtD
Triamcinolone—Pharyngitis—Docetaxel—ovarian cancer	0.000924	0.00144	CcSEcCtD
Triamcinolone—Urticaria—Vinorelbine—ovarian cancer	0.000922	0.00144	CcSEcCtD
Triamcinolone—Body temperature increased—Vinorelbine—ovarian cancer	0.000917	0.00143	CcSEcCtD
Triamcinolone—Osteoarthritis—Epirubicin—ovarian cancer	0.000908	0.00142	CcSEcCtD
Triamcinolone—Nausea—Chlorambucil—ovarian cancer	0.000905	0.00141	CcSEcCtD
Triamcinolone—Dizziness—Topotecan—ovarian cancer	0.000897	0.0014	CcSEcCtD
Triamcinolone—Increased appetite—Doxorubicin—ovarian cancer	0.000894	0.0014	CcSEcCtD
Triamcinolone—Affect lability—Epirubicin—ovarian cancer	0.000894	0.0014	CcSEcCtD
Triamcinolone—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000887	0.00139	CcSEcCtD
Triamcinolone—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000879	0.00137	CcSEcCtD
Triamcinolone—Angioedema—Paclitaxel—ovarian cancer	0.000874	0.00136	CcSEcCtD
Triamcinolone—Purpura—Doxorubicin—ovarian cancer	0.000872	0.00136	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000868	0.00136	CcSEcCtD
Triamcinolone—Cardiac arrest—Epirubicin—ovarian cancer	0.000863	0.00135	CcSEcCtD
Triamcinolone—Vomiting—Topotecan—ovarian cancer	0.000863	0.00135	CcSEcCtD
Triamcinolone—Malaise—Paclitaxel—ovarian cancer	0.000863	0.00135	CcSEcCtD
Triamcinolone—Mood swings—Epirubicin—ovarian cancer	0.00086	0.00134	CcSEcCtD
Triamcinolone—Vertigo—Paclitaxel—ovarian cancer	0.000859	0.00134	CcSEcCtD
Triamcinolone—Syncope—Paclitaxel—ovarian cancer	0.000858	0.00134	CcSEcCtD
Triamcinolone—Rash—Topotecan—ovarian cancer	0.000855	0.00134	CcSEcCtD
Triamcinolone—Hypersensitivity—Vinorelbine—ovarian cancer	0.000855	0.00133	CcSEcCtD
Triamcinolone—Dermatitis—Topotecan—ovarian cancer	0.000855	0.00133	CcSEcCtD
Triamcinolone—Headache—Topotecan—ovarian cancer	0.00085	0.00133	CcSEcCtD
Triamcinolone—Vomiting—Melphalan—ovarian cancer	0.000845	0.00132	CcSEcCtD
Triamcinolone—Loss of consciousness—Paclitaxel—ovarian cancer	0.000841	0.00131	CcSEcCtD
Triamcinolone—Osteoarthritis—Doxorubicin—ovarian cancer	0.00084	0.00131	CcSEcCtD
Triamcinolone—Rash—Melphalan—ovarian cancer	0.000838	0.00131	CcSEcCtD
Triamcinolone—Dermatitis—Melphalan—ovarian cancer	0.000837	0.00131	CcSEcCtD
Triamcinolone—Cough—Paclitaxel—ovarian cancer	0.000835	0.0013	CcSEcCtD
Triamcinolone—Asthenia—Vinorelbine—ovarian cancer	0.000833	0.0013	CcSEcCtD
Triamcinolone—Arrhythmia—Docetaxel—ovarian cancer	0.000832	0.0013	CcSEcCtD
Triamcinolone—Convulsion—Paclitaxel—ovarian cancer	0.000829	0.00129	CcSEcCtD
Triamcinolone—Affect lability—Doxorubicin—ovarian cancer	0.000827	0.00129	CcSEcCtD
Triamcinolone—Hypertension—Paclitaxel—ovarian cancer	0.000826	0.00129	CcSEcCtD
Triamcinolone—Pruritus—Vinorelbine—ovarian cancer	0.000821	0.00128	CcSEcCtD
Triamcinolone—Myalgia—Paclitaxel—ovarian cancer	0.000814	0.00127	CcSEcCtD
Triamcinolone—Erythema—Docetaxel—ovarian cancer	0.000811	0.00127	CcSEcCtD
Triamcinolone—Nausea—Topotecan—ovarian cancer	0.000806	0.00126	CcSEcCtD
Triamcinolone—Discomfort—Paclitaxel—ovarian cancer	0.000805	0.00126	CcSEcCtD
Triamcinolone—Muscular weakness—Epirubicin—ovarian cancer	0.000801	0.00125	CcSEcCtD
Triamcinolone—Cardiac arrest—Doxorubicin—ovarian cancer	0.000799	0.00125	CcSEcCtD
Triamcinolone—Dry mouth—Paclitaxel—ovarian cancer	0.000796	0.00124	CcSEcCtD
Triamcinolone—Mood swings—Doxorubicin—ovarian cancer	0.000796	0.00124	CcSEcCtD
Triamcinolone—Dysgeusia—Docetaxel—ovarian cancer	0.000794	0.00124	CcSEcCtD
Triamcinolone—Abdominal distension—Epirubicin—ovarian cancer	0.00079	0.00123	CcSEcCtD
Triamcinolone—Nausea—Melphalan—ovarian cancer	0.000789	0.00123	CcSEcCtD
Triamcinolone—Influenza—Epirubicin—ovarian cancer	0.000785	0.00123	CcSEcCtD
Triamcinolone—Asthma—Epirubicin—ovarian cancer	0.000785	0.00123	CcSEcCtD
Triamcinolone—Back pain—Docetaxel—ovarian cancer	0.000784	0.00122	CcSEcCtD
Triamcinolone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000781	0.00122	CcSEcCtD
Triamcinolone—Oedema—Paclitaxel—ovarian cancer	0.000781	0.00122	CcSEcCtD
Triamcinolone—Methylprednisolone—ABCB1—ovarian cancer	0.000777	0.0636	CrCbGaD
Triamcinolone—Infection—Paclitaxel—ovarian cancer	0.000775	0.00121	CcSEcCtD
Triamcinolone—Pancreatitis—Epirubicin—ovarian cancer	0.000769	0.0012	CcSEcCtD
Triamcinolone—Shock—Paclitaxel—ovarian cancer	0.000768	0.0012	CcSEcCtD
Triamcinolone—Dizziness—Vinorelbine—ovarian cancer	0.000767	0.0012	CcSEcCtD
Triamcinolone—Tachycardia—Paclitaxel—ovarian cancer	0.000762	0.00119	CcSEcCtD
Triamcinolone—Bronchitis—Epirubicin—ovarian cancer	0.000755	0.00118	CcSEcCtD
Triamcinolone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000755	0.00118	CcSEcCtD
Triamcinolone—Muscular weakness—Doxorubicin—ovarian cancer	0.000741	0.00116	CcSEcCtD
Triamcinolone—Vomiting—Vinorelbine—ovarian cancer	0.000738	0.00115	CcSEcCtD
Triamcinolone—Rash—Vinorelbine—ovarian cancer	0.000732	0.00114	CcSEcCtD
Triamcinolone—Dermatitis—Vinorelbine—ovarian cancer	0.000731	0.00114	CcSEcCtD
Triamcinolone—Abdominal distension—Doxorubicin—ovarian cancer	0.000731	0.00114	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000729	0.00114	CcSEcCtD
Triamcinolone—Headache—Vinorelbine—ovarian cancer	0.000727	0.00114	CcSEcCtD
Triamcinolone—Syncope—Docetaxel—ovarian cancer	0.000727	0.00114	CcSEcCtD
Triamcinolone—Asthma—Doxorubicin—ovarian cancer	0.000726	0.00113	CcSEcCtD
Triamcinolone—Influenza—Doxorubicin—ovarian cancer	0.000726	0.00113	CcSEcCtD
Triamcinolone—Weight increased—Epirubicin—ovarian cancer	0.000714	0.00112	CcSEcCtD
Triamcinolone—Loss of consciousness—Docetaxel—ovarian cancer	0.000713	0.00111	CcSEcCtD
Triamcinolone—Pancreatitis—Doxorubicin—ovarian cancer	0.000712	0.00111	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000711	0.00111	CcSEcCtD
Triamcinolone—Cough—Docetaxel—ovarian cancer	0.000707	0.0011	CcSEcCtD
Triamcinolone—Insomnia—Paclitaxel—ovarian cancer	0.000706	0.0011	CcSEcCtD
Triamcinolone—Convulsion—Docetaxel—ovarian cancer	0.000702	0.0011	CcSEcCtD
Triamcinolone—Paraesthesia—Paclitaxel—ovarian cancer	0.000701	0.00109	CcSEcCtD
Triamcinolone—Hypertension—Docetaxel—ovarian cancer	0.0007	0.00109	CcSEcCtD
Triamcinolone—Bronchitis—Doxorubicin—ovarian cancer	0.000698	0.00109	CcSEcCtD
Triamcinolone—Dyspnoea—Paclitaxel—ovarian cancer	0.000696	0.00109	CcSEcCtD
Triamcinolone—Myalgia—Docetaxel—ovarian cancer	0.00069	0.00108	CcSEcCtD
Triamcinolone—Nausea—Vinorelbine—ovarian cancer	0.000689	0.00108	CcSEcCtD
Triamcinolone—Dyspepsia—Paclitaxel—ovarian cancer	0.000687	0.00107	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000686	0.00107	CcSEcCtD
Triamcinolone—Conjunctivitis—Epirubicin—ovarian cancer	0.00068	0.00106	CcSEcCtD
Triamcinolone—Dry mouth—Docetaxel—ovarian cancer	0.000675	0.00105	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000675	0.00105	CcSEcCtD
Triamcinolone—Fatigue—Paclitaxel—ovarian cancer	0.000673	0.00105	CcSEcCtD
Triamcinolone—Pain—Paclitaxel—ovarian cancer	0.000668	0.00104	CcSEcCtD
Triamcinolone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000662	0.00103	CcSEcCtD
Triamcinolone—Oedema—Docetaxel—ovarian cancer	0.000662	0.00103	CcSEcCtD
Triamcinolone—Weight increased—Doxorubicin—ovarian cancer	0.000661	0.00103	CcSEcCtD
Triamcinolone—Epistaxis—Epirubicin—ovarian cancer	0.00066	0.00103	CcSEcCtD
Triamcinolone—Infection—Docetaxel—ovarian cancer	0.000657	0.00103	CcSEcCtD
Triamcinolone—Shock—Docetaxel—ovarian cancer	0.000651	0.00102	CcSEcCtD
Triamcinolone—Tachycardia—Docetaxel—ovarian cancer	0.000646	0.00101	CcSEcCtD
Triamcinolone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000643	0.001	CcSEcCtD
Triamcinolone—Bradycardia—Epirubicin—ovarian cancer	0.000639	0.000998	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000635	0.000991	CcSEcCtD
Triamcinolone—Haemoglobin—Epirubicin—ovarian cancer	0.000631	0.000986	CcSEcCtD
Triamcinolone—Rhinitis—Epirubicin—ovarian cancer	0.00063	0.000983	CcSEcCtD
Triamcinolone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000629	0.000983	CcSEcCtD
Triamcinolone—Haemorrhage—Epirubicin—ovarian cancer	0.000628	0.000981	CcSEcCtD
Triamcinolone—Pharyngitis—Epirubicin—ovarian cancer	0.000623	0.000973	CcSEcCtD
Triamcinolone—Urticaria—Paclitaxel—ovarian cancer	0.00062	0.000968	CcSEcCtD
Triamcinolone—Body temperature increased—Paclitaxel—ovarian cancer	0.000617	0.000963	CcSEcCtD
Triamcinolone—Epistaxis—Doxorubicin—ovarian cancer	0.000611	0.000953	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000603	0.000941	CcSEcCtD
Triamcinolone—Insomnia—Docetaxel—ovarian cancer	0.000598	0.000934	CcSEcCtD
Triamcinolone—Prednisone—ABCB1—ovarian cancer	0.000594	0.0486	CrCbGaD
Triamcinolone—Paraesthesia—Docetaxel—ovarian cancer	0.000594	0.000928	CcSEcCtD
Triamcinolone—Bradycardia—Doxorubicin—ovarian cancer	0.000592	0.000924	CcSEcCtD
Triamcinolone—Dyspnoea—Docetaxel—ovarian cancer	0.00059	0.000921	CcSEcCtD
Triamcinolone—Haemoglobin—Doxorubicin—ovarian cancer	0.000584	0.000912	CcSEcCtD
Triamcinolone—Rhinitis—Doxorubicin—ovarian cancer	0.000583	0.00091	CcSEcCtD
Triamcinolone—Dyspepsia—Docetaxel—ovarian cancer	0.000582	0.000909	CcSEcCtD
Triamcinolone—Haemorrhage—Doxorubicin—ovarian cancer	0.000581	0.000907	CcSEcCtD
Triamcinolone—Pharyngitis—Doxorubicin—ovarian cancer	0.000577	0.000901	CcSEcCtD
Triamcinolone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000575	0.000898	CcSEcCtD
Triamcinolone—Fatigue—Docetaxel—ovarian cancer	0.00057	0.000891	CcSEcCtD
Triamcinolone—Pain—Docetaxel—ovarian cancer	0.000566	0.000883	CcSEcCtD
Triamcinolone—Arrhythmia—Epirubicin—ovarian cancer	0.000561	0.000876	CcSEcCtD
Triamcinolone—Asthenia—Paclitaxel—ovarian cancer	0.00056	0.000874	CcSEcCtD
Triamcinolone—Pruritus—Paclitaxel—ovarian cancer	0.000552	0.000862	CcSEcCtD
Triamcinolone—Prednisolone—ABCB1—ovarian cancer	0.000548	0.0448	CrCbGaD
Triamcinolone—Erythema—Epirubicin—ovarian cancer	0.000547	0.000854	CcSEcCtD
Triamcinolone—Feeling abnormal—Docetaxel—ovarian cancer	0.000545	0.000851	CcSEcCtD
Triamcinolone—Betamethasone—ABCB1—ovarian cancer	0.000537	0.0439	CrCbGaD
Triamcinolone—Dysgeusia—Epirubicin—ovarian cancer	0.000535	0.000836	CcSEcCtD
Triamcinolone—Back pain—Epirubicin—ovarian cancer	0.000529	0.000826	CcSEcCtD
Triamcinolone—Body temperature increased—Docetaxel—ovarian cancer	0.000523	0.000817	CcSEcCtD
Triamcinolone—Arrhythmia—Doxorubicin—ovarian cancer	0.000519	0.000811	CcSEcCtD
Triamcinolone—Dizziness—Paclitaxel—ovarian cancer	0.000516	0.000806	CcSEcCtD
Triamcinolone—Ill-defined disorder—Epirubicin—ovarian cancer	0.000507	0.000792	CcSEcCtD
Triamcinolone—Erythema—Doxorubicin—ovarian cancer	0.000506	0.00079	CcSEcCtD
Triamcinolone—Vomiting—Paclitaxel—ovarian cancer	0.000496	0.000775	CcSEcCtD
Triamcinolone—Dysgeusia—Doxorubicin—ovarian cancer	0.000495	0.000774	CcSEcCtD
Triamcinolone—Malaise—Epirubicin—ovarian cancer	0.000493	0.00077	CcSEcCtD
Triamcinolone—Rash—Paclitaxel—ovarian cancer	0.000492	0.000768	CcSEcCtD
Triamcinolone—Dermatitis—Paclitaxel—ovarian cancer	0.000492	0.000768	CcSEcCtD
Triamcinolone—Vertigo—Epirubicin—ovarian cancer	0.000491	0.000767	CcSEcCtD
Triamcinolone—Syncope—Epirubicin—ovarian cancer	0.00049	0.000766	CcSEcCtD
Triamcinolone—Back pain—Doxorubicin—ovarian cancer	0.000489	0.000764	CcSEcCtD
Triamcinolone—Headache—Paclitaxel—ovarian cancer	0.000489	0.000763	CcSEcCtD
Triamcinolone—Hypersensitivity—Docetaxel—ovarian cancer	0.000487	0.000761	CcSEcCtD
Triamcinolone—Loss of consciousness—Epirubicin—ovarian cancer	0.000481	0.00075	CcSEcCtD
Triamcinolone—Cough—Epirubicin—ovarian cancer	0.000477	0.000745	CcSEcCtD
Triamcinolone—Asthenia—Docetaxel—ovarian cancer	0.000475	0.000741	CcSEcCtD
Triamcinolone—Convulsion—Epirubicin—ovarian cancer	0.000474	0.00074	CcSEcCtD
Triamcinolone—Hypertension—Epirubicin—ovarian cancer	0.000472	0.000737	CcSEcCtD
Triamcinolone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000469	0.000733	CcSEcCtD
Triamcinolone—Pruritus—Docetaxel—ovarian cancer	0.000468	0.000731	CcSEcCtD
Triamcinolone—Myalgia—Epirubicin—ovarian cancer	0.000466	0.000727	CcSEcCtD
Triamcinolone—Nausea—Paclitaxel—ovarian cancer	0.000464	0.000724	CcSEcCtD
Triamcinolone—Discomfort—Epirubicin—ovarian cancer	0.00046	0.000718	CcSEcCtD
Triamcinolone—Malaise—Doxorubicin—ovarian cancer	0.000456	0.000712	CcSEcCtD
Triamcinolone—Dry mouth—Epirubicin—ovarian cancer	0.000455	0.000711	CcSEcCtD
Triamcinolone—Vertigo—Doxorubicin—ovarian cancer	0.000455	0.00071	CcSEcCtD
Triamcinolone—Syncope—Doxorubicin—ovarian cancer	0.000454	0.000708	CcSEcCtD
Triamcinolone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000446	0.000697	CcSEcCtD
Triamcinolone—Oedema—Epirubicin—ovarian cancer	0.000446	0.000697	CcSEcCtD
Triamcinolone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000445	0.000694	CcSEcCtD
Triamcinolone—Infection—Epirubicin—ovarian cancer	0.000443	0.000692	CcSEcCtD
Triamcinolone—Cough—Doxorubicin—ovarian cancer	0.000441	0.000689	CcSEcCtD
Triamcinolone—Shock—Epirubicin—ovarian cancer	0.000439	0.000685	CcSEcCtD
Triamcinolone—Convulsion—Doxorubicin—ovarian cancer	0.000438	0.000684	CcSEcCtD
Triamcinolone—Dizziness—Docetaxel—ovarian cancer	0.000438	0.000683	CcSEcCtD
Triamcinolone—Hypertension—Doxorubicin—ovarian cancer	0.000437	0.000682	CcSEcCtD
Triamcinolone—Tachycardia—Epirubicin—ovarian cancer	0.000436	0.00068	CcSEcCtD
Triamcinolone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000431	0.000674	CcSEcCtD
Triamcinolone—Myalgia—Doxorubicin—ovarian cancer	0.000431	0.000673	CcSEcCtD
Triamcinolone—Discomfort—Doxorubicin—ovarian cancer	0.000426	0.000664	CcSEcCtD
Triamcinolone—Dry mouth—Doxorubicin—ovarian cancer	0.000421	0.000658	CcSEcCtD
Triamcinolone—Vomiting—Docetaxel—ovarian cancer	0.000421	0.000657	CcSEcCtD
Triamcinolone—Hydrocortisone—ABCB1—ovarian cancer	0.000419	0.0343	CrCbGaD
Triamcinolone—Rash—Docetaxel—ovarian cancer	0.000417	0.000651	CcSEcCtD
Triamcinolone—Dermatitis—Docetaxel—ovarian cancer	0.000417	0.000651	CcSEcCtD
Triamcinolone—Headache—Docetaxel—ovarian cancer	0.000414	0.000647	CcSEcCtD
Triamcinolone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000413	0.000645	CcSEcCtD
Triamcinolone—Oedema—Doxorubicin—ovarian cancer	0.000413	0.000645	CcSEcCtD
Triamcinolone—Infection—Doxorubicin—ovarian cancer	0.00041	0.00064	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000407	0.000635	CcSEcCtD
Triamcinolone—Shock—Doxorubicin—ovarian cancer	0.000406	0.000634	CcSEcCtD
Triamcinolone—Insomnia—Epirubicin—ovarian cancer	0.000404	0.00063	CcSEcCtD
Triamcinolone—Tachycardia—Doxorubicin—ovarian cancer	0.000403	0.000629	CcSEcCtD
Triamcinolone—Paraesthesia—Epirubicin—ovarian cancer	0.000401	0.000626	CcSEcCtD
Triamcinolone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000399	0.000623	CcSEcCtD
Triamcinolone—Dyspnoea—Epirubicin—ovarian cancer	0.000398	0.000621	CcSEcCtD
Triamcinolone—Nausea—Docetaxel—ovarian cancer	0.000393	0.000614	CcSEcCtD
Triamcinolone—Dyspepsia—Epirubicin—ovarian cancer	0.000393	0.000613	CcSEcCtD
Triamcinolone—Fatigue—Epirubicin—ovarian cancer	0.000385	0.000601	CcSEcCtD
Triamcinolone—Pain—Epirubicin—ovarian cancer	0.000382	0.000596	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000376	0.000587	CcSEcCtD
Triamcinolone—Insomnia—Doxorubicin—ovarian cancer	0.000373	0.000583	CcSEcCtD
Triamcinolone—Paraesthesia—Doxorubicin—ovarian cancer	0.000371	0.000579	CcSEcCtD
Triamcinolone—Dyspnoea—Doxorubicin—ovarian cancer	0.000368	0.000575	CcSEcCtD
Triamcinolone—Feeling abnormal—Epirubicin—ovarian cancer	0.000368	0.000574	CcSEcCtD
Triamcinolone—Dyspepsia—Doxorubicin—ovarian cancer	0.000363	0.000567	CcSEcCtD
Triamcinolone—Fatigue—Doxorubicin—ovarian cancer	0.000356	0.000556	CcSEcCtD
Triamcinolone—Urticaria—Epirubicin—ovarian cancer	0.000355	0.000554	CcSEcCtD
Triamcinolone—Pain—Doxorubicin—ovarian cancer	0.000353	0.000551	CcSEcCtD
Triamcinolone—Body temperature increased—Epirubicin—ovarian cancer	0.000353	0.000551	CcSEcCtD
Triamcinolone—Feeling abnormal—Doxorubicin—ovarian cancer	0.00034	0.000531	CcSEcCtD
Triamcinolone—Hypersensitivity—Epirubicin—ovarian cancer	0.000329	0.000513	CcSEcCtD
Triamcinolone—Urticaria—Doxorubicin—ovarian cancer	0.000328	0.000512	CcSEcCtD
Triamcinolone—Body temperature increased—Doxorubicin—ovarian cancer	0.000326	0.00051	CcSEcCtD
Triamcinolone—Asthenia—Epirubicin—ovarian cancer	0.00032	0.0005	CcSEcCtD
Triamcinolone—Pruritus—Epirubicin—ovarian cancer	0.000316	0.000493	CcSEcCtD
Triamcinolone—Dexamethasone—ABCB1—ovarian cancer	0.000312	0.0255	CrCbGaD
Triamcinolone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000304	0.000475	CcSEcCtD
Triamcinolone—Asthenia—Doxorubicin—ovarian cancer	0.000296	0.000463	CcSEcCtD
Triamcinolone—Dizziness—Epirubicin—ovarian cancer	0.000295	0.000461	CcSEcCtD
Triamcinolone—Pruritus—Doxorubicin—ovarian cancer	0.000292	0.000456	CcSEcCtD
Triamcinolone—Vomiting—Epirubicin—ovarian cancer	0.000284	0.000443	CcSEcCtD
Triamcinolone—Rash—Epirubicin—ovarian cancer	0.000281	0.000439	CcSEcCtD
Triamcinolone—Dermatitis—Epirubicin—ovarian cancer	0.000281	0.000439	CcSEcCtD
Triamcinolone—Headache—Epirubicin—ovarian cancer	0.00028	0.000436	CcSEcCtD
Triamcinolone—Dizziness—Doxorubicin—ovarian cancer	0.000273	0.000426	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000269	0.0061	CbGpPWpGaD
Triamcinolone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	0.000268	0.00609	CbGpPWpGaD
Triamcinolone—Nausea—Epirubicin—ovarian cancer	0.000265	0.000414	CcSEcCtD
Triamcinolone—Vomiting—Doxorubicin—ovarian cancer	0.000263	0.00041	CcSEcCtD
Triamcinolone—Rash—Doxorubicin—ovarian cancer	0.00026	0.000406	CcSEcCtD
Triamcinolone—Dermatitis—Doxorubicin—ovarian cancer	0.00026	0.000406	CcSEcCtD
Triamcinolone—Headache—Doxorubicin—ovarian cancer	0.000259	0.000404	CcSEcCtD
Triamcinolone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—ovarian cancer	0.000258	0.00587	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—MUC16—ovarian cancer	0.000256	0.00581	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—ESR1—ovarian cancer	0.000253	0.00575	CbGpPWpGaD
Triamcinolone—NR3C1—Transcription factor regulation in adipogenesis—IL6—ovarian cancer	0.00025	0.00568	CbGpPWpGaD
Triamcinolone—Nausea—Doxorubicin—ovarian cancer	0.000245	0.000383	CcSEcCtD
Triamcinolone—NR3C1—Endoderm Differentiation—APC—ovarian cancer	0.000245	0.00557	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—SOD1—ovarian cancer	0.000227	0.00515	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.000225	0.00512	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—GADD45A—ovarian cancer	0.000221	0.00502	CbGpPWpGaD
Triamcinolone—PTGS2—Overview of nanoparticle effects—IL6—ovarian cancer	0.000213	0.00484	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000212	0.00481	CbGpPWpGaD
Triamcinolone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000206	0.00467	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000204	0.00464	CbGpPWpGaD
Triamcinolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000196	0.00445	CbGpPWpGaD
Triamcinolone—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000187	0.00424	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.000183	0.00415	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CXCL8—ovarian cancer	0.000176	0.004	CbGpPWpGaD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	0.000175	0.00397	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CDKN1B—ovarian cancer	0.000172	0.00391	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—IL2—ovarian cancer	0.000169	0.00383	CbGpPWpGaD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	0.000167	0.0038	CbGpPWpGaD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	0.000167	0.0038	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000167	0.00379	CbGpPWpGaD
Triamcinolone—NR3C1—Endoderm Differentiation—CTNNB1—ovarian cancer	0.000167	0.00378	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—INHA—ovarian cancer	0.000165	0.00375	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CCND1—ovarian cancer	0.000164	0.00373	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CTNNB1—ovarian cancer	0.000163	0.00369	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—MMP9—ovarian cancer	0.00016	0.00362	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—PTEN—ovarian cancer	0.000159	0.0036	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—ovarian cancer	0.000155	0.00353	CbGpPWpGaD
Triamcinolone—BCHE—Peptide hormone metabolism—CTNNB1—ovarian cancer	0.000153	0.00348	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PIK3CG—ovarian cancer	0.000153	0.00348	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—IL6ST—ovarian cancer	0.000152	0.00345	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	0.000152	0.00345	CbGpPWpGaD
Triamcinolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000151	0.00343	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.00015	0.00342	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	0.00015	0.00341	CbGpPWpGaD
Triamcinolone—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000149	0.00339	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—IL2—ovarian cancer	0.000148	0.00337	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—WDR77—ovarian cancer	0.000143	0.00325	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000143	0.00324	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.00014	0.00317	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000137	0.00312	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.000137	0.0031	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.000137	0.0031	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PIK3CD—ovarian cancer	0.000135	0.00306	CbGpPWpGaD
Triamcinolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.000132	0.00301	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NME2—ovarian cancer	0.000132	0.003	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—MYC—ovarian cancer	0.000132	0.00299	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	0.00013	0.00295	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.000129	0.00293	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000129	0.00292	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000122	0.00278	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—YAP1—ovarian cancer	0.000121	0.00275	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—ovarian cancer	0.000119	0.00271	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HSD17B6—ovarian cancer	0.000119	0.00269	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PIK3CB—ovarian cancer	0.000117	0.00267	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000117	0.00266	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000116	0.00264	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—TUBB3—ovarian cancer	0.000116	0.00264	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000115	0.00261	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—ovarian cancer	0.000114	0.00258	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000113	0.00256	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000113	0.00256	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000113	0.00256	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—TTF1—ovarian cancer	0.000112	0.00255	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000112	0.00254	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000111	0.00252	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	0.00011	0.00249	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—TP53—ovarian cancer	0.000108	0.00246	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	0.000108	0.00244	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—PGR—ovarian cancer	0.000106	0.0024	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—NR5A1—ovarian cancer	0.000102	0.00232	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PTEN—ovarian cancer	0.000101	0.0023	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—CTNNB1—ovarian cancer	9.92e-05	0.00225	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—IL6—ovarian cancer	9.91e-05	0.00225	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—PARP1—ovarian cancer	9.82e-05	0.00223	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—ATF3—ovarian cancer	9.81e-05	0.00223	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—ovarian cancer	9.54e-05	0.00217	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CHMP4C—ovarian cancer	9.48e-05	0.00215	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	9.29e-05	0.00211	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	9.27e-05	0.0021	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	9.12e-05	0.00207	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NME2—ovarian cancer	9.08e-05	0.00206	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	8.89e-05	0.00202	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	8.8e-05	0.002	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—IL6—ovarian cancer	8.73e-05	0.00198	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—STAT3—ovarian cancer	8.64e-05	0.00196	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	8.63e-05	0.00196	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	8.6e-05	0.00195	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	8.6e-05	0.00195	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	8.57e-05	0.00195	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYTB—ovarian cancer	8.5e-05	0.00193	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	8.42e-05	0.00191	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	8.41e-05	0.00191	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	8.31e-05	0.00189	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—BCL9—ovarian cancer	8.22e-05	0.00187	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	8.2e-05	0.00186	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	8.13e-05	0.00185	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	8.13e-05	0.00185	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—ovarian cancer	8.05e-05	0.00183	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	7.98e-05	0.00181	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	7.96e-05	0.00181	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	7.7e-05	0.00175	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	7.54e-05	0.00171	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—BRIP1—ovarian cancer	7.43e-05	0.00169	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PPP1CC—ovarian cancer	7.43e-05	0.00169	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PIK3CA—ovarian cancer	7.16e-05	0.00163	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	6.78e-05	0.00154	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	6.76e-05	0.00154	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	6.58e-05	0.00149	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	6.51e-05	0.00148	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	6.43e-05	0.00146	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	6.43e-05	0.00146	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	6.42e-05	0.00146	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	6.31e-05	0.00143	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.28e-05	0.00143	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	6.25e-05	0.00142	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—MAPK1—ovarian cancer	6.13e-05	0.00139	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PPP1CC—ovarian cancer	6.11e-05	0.00139	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—IL6—ovarian cancer	6.04e-05	0.00137	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYTB—ovarian cancer	5.85e-05	0.00133	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	5.85e-05	0.00133	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—YAP1—ovarian cancer	5.82e-05	0.00132	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	5.73e-05	0.0013	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.72e-05	0.0013	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ESR1—ovarian cancer	5.64e-05	0.00128	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	5.58e-05	0.00127	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	5.52e-05	0.00125	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.42e-05	0.00123	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	5.4e-05	0.00123	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	5.38e-05	0.00122	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—IL6—ovarian cancer	5.22e-05	0.00118	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—BRIP1—ovarian cancer	5.12e-05	0.00116	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PPP1CC—ovarian cancer	5.12e-05	0.00116	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PGR—ovarian cancer	5.08e-05	0.00115	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—YAP1—ovarian cancer	4.98e-05	0.00113	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	4.94e-05	0.00112	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.93e-05	0.00112	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.92e-05	0.00112	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	4.86e-05	0.0011	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PARP1—ovarian cancer	4.73e-05	0.00107	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—MAPK1—ovarian cancer	4.7e-05	0.00107	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HDAC6—ovarian cancer	4.63e-05	0.00105	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	4.6e-05	0.00104	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	4.47e-05	0.00102	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	4.38e-05	0.000994	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	4.38e-05	0.000994	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.34e-05	0.000985	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	4.13e-05	0.000939	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—FASN—ovarian cancer	4.06e-05	0.000923	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—XIAP—ovarian cancer	4.01e-05	0.000911	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SLC5A5—ovarian cancer	4e-05	0.000908	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NME2—ovarian cancer	3.97e-05	0.000901	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SMARCA4—ovarian cancer	3.91e-05	0.000888	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SLC2A1—ovarian cancer	3.86e-05	0.000877	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PPP2R1A—ovarian cancer	3.83e-05	0.000871	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EREG—ovarian cancer	3.82e-05	0.000867	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.8e-05	0.000862	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.78e-05	0.000858	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—MMP2—ovarian cancer	3.78e-05	0.000858	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—HRAS—ovarian cancer	3.77e-05	0.000856	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.73e-05	0.000846	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP1B1—ovarian cancer	3.7e-05	0.00084	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	3.67e-05	0.000834	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—YAP1—ovarian cancer	3.43e-05	0.000779	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.4e-05	0.000771	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—FASN—ovarian cancer	3.34e-05	0.000758	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PARP1—ovarian cancer	3.33e-05	0.000755	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PPP2R1A—ovarian cancer	3.28e-05	0.000745	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.27e-05	0.000742	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SLC2A1—ovarian cancer	3.17e-05	0.00072	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CXCL8—ovarian cancer	3.14e-05	0.000713	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.1e-05	0.000705	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ABCB1—ovarian cancer	3.05e-05	0.000692	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TYMS—ovarian cancer	2.99e-05	0.00068	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.98e-05	0.000678	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—MYC—ovarian cancer	2.93e-05	0.000666	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CTNNB1—ovarian cancer	2.9e-05	0.000658	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—FASN—ovarian cancer	2.8e-05	0.000635	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SLC5A5—ovarian cancer	2.75e-05	0.000625	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ESR1—ovarian cancer	2.71e-05	0.000616	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PPP2R1A—ovarian cancer	2.7e-05	0.000613	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SLC2A1—ovarian cancer	2.66e-05	0.000603	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.6e-05	0.000591	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYTB—ovarian cancer	2.56e-05	0.00058	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP1B1—ovarian cancer	2.55e-05	0.000578	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CAV1—ovarian cancer	2.41e-05	0.000548	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.3e-05	0.000523	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PPP2R1A—ovarian cancer	2.26e-05	0.000513	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.25e-05	0.000511	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.23e-05	0.000507	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.23e-05	0.000507	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PIK3CG—ovarian cancer	2.2e-05	0.000499	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TERT—ovarian cancer	2.14e-05	0.000487	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ABCB1—ovarian cancer	2.1e-05	0.000476	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TYMS—ovarian cancer	2.06e-05	0.000468	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CAV1—ovarian cancer	1.98e-05	0.00045	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PIK3CD—ovarian cancer	1.93e-05	0.000439	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—IL6ST—ovarian cancer	1.88e-05	0.000427	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—APC—ovarian cancer	1.81e-05	0.00041	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PIK3CB—ovarian cancer	1.68e-05	0.000382	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CAV1—ovarian cancer	1.66e-05	0.000377	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PIK3CD—ovarian cancer	1.59e-05	0.00036	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.59e-05	0.00036	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PIK3CG—ovarian cancer	1.51e-05	0.000343	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—YAP1—ovarian cancer	1.5e-05	0.00034	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTEN—ovarian cancer	1.45e-05	0.00033	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—MAPK3—ovarian cancer	1.45e-05	0.00033	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—MYC—ovarian cancer	1.41e-05	0.000321	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ERBB2—ovarian cancer	1.4e-05	0.000318	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MTOR—ovarian cancer	1.38e-05	0.000314	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PIK3CB—ovarian cancer	1.38e-05	0.000314	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PIK3CD—ovarian cancer	1.33e-05	0.000302	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CDKN1B—ovarian cancer	1.3e-05	0.000295	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CTNNB1—ovarian cancer	1.23e-05	0.000279	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—FASN—ovarian cancer	1.22e-05	0.000277	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.2e-05	0.000273	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PTEN—ovarian cancer	1.2e-05	0.000271	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.16e-05	0.000264	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PIK3CB—ovarian cancer	1.16e-05	0.000263	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.11e-05	0.000253	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—STAT3—ovarian cancer	1.07e-05	0.000243	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NRAS—ovarian cancer	1.07e-05	0.000242	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PIK3CA—ovarian cancer	1.03e-05	0.000233	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MAPK3—ovarian cancer	1.02e-05	0.000232	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PTEN—ovarian cancer	1e-05	0.000227	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MYC—ovarian cancer	9.93e-06	0.000226	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	9.87e-06	0.000224	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—AKT1—ovarian cancer	9.79e-06	0.000222	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MAPK1—ovarian cancer	9.72e-06	0.000221	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EGFR—ovarian cancer	9.72e-06	0.000221	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—KRAS—ovarian cancer	9.18e-06	0.000208	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ABCB1—ovarian cancer	9.16e-06	0.000208	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TYMS—ovarian cancer	9e-06	0.000204	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PIK3CA—ovarian cancer	8.43e-06	0.000192	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—AKT1—ovarian cancer	8.38e-06	0.00019	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HRAS—ovarian cancer	7.8e-06	0.000177	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—IL6—ovarian cancer	7.47e-06	0.00017	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CAV1—ovarian cancer	7.25e-06	0.000165	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PIK3CA—ovarian cancer	7.06e-06	0.00016	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—AKT1—ovarian cancer	6.89e-06	0.000156	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	6.6e-06	0.00015	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	5.81e-06	0.000132	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—AKT1—ovarian cancer	5.77e-06	0.000131	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.06e-06	0.000115	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTEN—ovarian cancer	4.37e-06	9.93e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.08e-06	7e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—AKT1—ovarian cancer	2.52e-06	5.72e-05	CbGpPWpGaD
